Asciminib (Scemblix) is a protein kinase inhibitor which specifically targets the ABL myristoyl pocket of the fusion protein Bcr-ABL. It is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML). The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.